BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12116028)

  • 1. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
    J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan.
    Lin HJ; Cherng JM; Hung MS; Sayion Y; Lin JC
    J Biomed Sci; 2005 Dec; 12(6):925-36. PubMed ID: 16307312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
    Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
    Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
    Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
    J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers.
    Benninger-Döring G; Pepperl S; Deml L; Modrow S; Wolf H; Jilg W
    Virology; 1999 Nov; 264(2):289-97. PubMed ID: 10562493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of CD8+ T-cell epitopes specific for immediate-early transactivator Rta of Epstein-Barr virus.
    Yu H; Srinivasan N; Ren E; Chan S
    Hum Immunol; 2005 May; 66(5):483-93. PubMed ID: 15935885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W; Fong C
    Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.
    Lin X; Chen S; Xue X; Lu L; Zhu S; Li W; Chen X; Zhong X; Jiang P; Sename TS; Zheng Y; Zhang L
    Cell Mol Immunol; 2016 Jul; 13(4):492-501. PubMed ID: 25864917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro.
    Cheung WH; Chan VS; Pang HW; Wong MK; Guo ZH; Tam PK; Che CM; Lin CL; Yu WY
    Bioconjug Chem; 2009 Jan; 20(1):24-31. PubMed ID: 19102689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Fogg MH; Wirth LJ; Posner M; Wang F
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
    Straathof KC; Leen AM; Buza EL; Taylor G; Huls MH; Heslop HE; Rooney CM; Bollard CM
    J Immunol; 2005 Sep; 175(6):4137-47. PubMed ID: 16148164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
    Lin X; Gudgeon NH; Hui EP; Jia H; Qun X; Taylor GS; Barnardo MC; Lin CK; Rickinson AB; Chan AT
    Cancer Immunol Immunother; 2008 Jul; 57(7):963-75. PubMed ID: 18094968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.